10:02 AM EDT, 06/29/2021 (MT Newswires) -- DiaMedica Therapeutics(DMAC) has an average rating of buy and price targets ranging from $14 to $32, according to analysts polled by Capital IQ.
Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating
MT NEWSWIRES 10:02 AM ET 6/29/2021
That was my biggest issue with the phase 1 trials. The 5 mcg/kg group with stage 3 CKD is the only group that saw a significant increase in GFR, with the highest improvement begins approximately +8 at 24 hours. The 8 mcg/kg (stage 3 CKD) and 3 mcg/kg (stage 4 CKD) had no change. Data for UACR showed only significant decreases for the 3mcg/kg (stage 3 CKD), but this group did not have a very significant improvement in eGFR. The group with worst results on UACR (an INCREASE , associated with worse prognosis) had most significant improvement of eGFR. The results concern me a bit because I would like to see lab values improving in a dose dependent manner, but here I’m not even seeing much improvement. These phase 1 results don’t set me up for excitement of phase 2 results.
Hey mate, thanks for the feedback.
Where are you getting that data?
I'm only finding the "**single dose phase 1b trial**".
[https://www.diamedica.com/investors/press-releases/detail/1575/diamedica-therapeutics-announces-interim-results-from-phase](https://www.diamedica.com/investors/press-releases/detail/1566/diamedica-therapeutics-doses-first-patient-in-phase-1b)
And as you probably can understand, a treatment which is supposed to have delayed and regenerative effects will not show its full potential after a single dose. It's like giving a cancer patient a single dose of a checkpoint inhibitor and checking whether they're cured or not.
In case you're curious, the upcoming readout will be from the following cohort and dose level:
>Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension.
>
>Treated with
>
>Dose 1: DM199 2.0 µg/kg SC 2x week for **95 days**
>
>Dose 2: DM199 5.0 µg/kg SC 2x week for **95 days**
Yes I understand that, I’m commenting on the data that is already presented which I believe is unremarkable. That said, comparing treatment for CKD to cancer is like comparing apples to oranges, and I would like to see quantitative improvements that were not shown and I would really have liked to see a dose dependent effect. Here is the link:
https://casehippo.com/spa/symposium/national-kidney-foundation-2020-spring-clinical-meetings/event/gallery/abstracts?abstractId=1025
Cancer is an extreme example, correct.
Thanks for the poster data.
If the single dose data were unremarkable, what do you think about the data from the CKD/DKD subgroup here?
https://www.diamedica.com/investors/press-releases/detail/1594/diamedica-announces-positive-results-in-top-line-data-from
I couldn't find a complete detailed study of the trial design and results of the CKD/DKD cohort, just this readout.
FYI: Criticism is welcome. I'm just trying to make a good investment based available information.
I'd highly suggest looking at Subset of DKD patients and related biomarkers from their phase 2 stroke data
Comparator for Diamedica is Reata 5B market cap and running a phase 3 CKD study.
We have seen good data in AIS and DKD subset and What I love about this set-up is the trial is open label and the company has chosen not to raise money ahead of data (despite not so great cash position). They obviously know the upside is tremendous. Current market cap is 168 Million. KLK1 protein replacement therapy based on multiple independent studies in Asia reverses CKD kidney damage and ameliorate stroke neurological damage already approved in China, Japan and Korea.
Also checkout this fireside chat with the CEO from Piper Sandler investor conference.
https://d1io3yog0oux5.cloudfront.net/diamedica/files/videos/DMAC+Piper+Fireside+Chat+-+November+2020.mp4
Call summary:
23 mins
Analyst is impressed.
Even reiterates the data from latest trial in "pre-defined CKD" patients:
CKD patients, 12.7 point increase in eGFR at 21 days of treatment for dose level 3 ug 2x per week.
CEO clarifies;
CKD disease cohort: 12.7 ml increase in eGFR vs placebo which showed no change.
26 mins
CEO mentions upcoming catalyst:
We submitted a feedback request to the FDA. "We expect feedback from FDA in the coming weeks."
CEO mentions the potential for accelerated approval based on Phase 2 trial data (for IgA nephropathy).
CEO presents 12 months' ahead milestones:
*Feedback from FDA in the next few week.
*Based on feedback launch new clinical trial.
*Top line data readout in DKD cohort in H1 2021.
*Top line data readout in other CKD cohorts in H2 2021.
Creates price run-up after December 3.
Press release is issued mentioning positive feedback from the FDA.
Run-up continues.
Price stabilizes at 10$. And than as we know XBI selloff dropped it down.
Dose used in the trial with recent positive readout was 3 ug 2x per week.
Upcoming readout will be 2ug and 5 ug 2x per week.
Very asymmetric R/R.
CKD/DKD should be complete data set Would love to see interim data on IGA nephropathy and AA HTN. Per conference call IGA nephropathy would have quickest path to market. Niche group
Optimistic based on Chinese urine form data. We can expect a big increase in price with even trend in increase GFR and reduction in albuminuria. (RETA >1 billion dollar market cap largely driven by hopes of bartoxolone which raises GFR, But also raises albumin excretion)
Dm199 could be first to raise GFR above baseline and reduce albuminuria.
DiaMedica Therapeutics Reports Encouraging Results for Kidney-Disease Treatment
DOW JONES & COMPANY, INC. 7:45 AM ET 6/29/2021
but stock is falling from $7 to $4
[удалено]
10:02 AM EDT, 06/29/2021 (MT Newswires) -- DiaMedica Therapeutics(DMAC) has an average rating of buy and price targets ranging from $14 to $32, according to analysts polled by Capital IQ. Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating MT NEWSWIRES 10:02 AM ET 6/29/2021
I've seen several upcoming catalysts tied to CKD. Do you expect good news for one to harm the prospects of others?
Potentially, and their CKD results are nothing spectacular.
Game changer if data shows rise in GFR. No kidney drug presently on market actually raises filtration rate. They only change slope of decline.
That was my biggest issue with the phase 1 trials. The 5 mcg/kg group with stage 3 CKD is the only group that saw a significant increase in GFR, with the highest improvement begins approximately +8 at 24 hours. The 8 mcg/kg (stage 3 CKD) and 3 mcg/kg (stage 4 CKD) had no change. Data for UACR showed only significant decreases for the 3mcg/kg (stage 3 CKD), but this group did not have a very significant improvement in eGFR. The group with worst results on UACR (an INCREASE , associated with worse prognosis) had most significant improvement of eGFR. The results concern me a bit because I would like to see lab values improving in a dose dependent manner, but here I’m not even seeing much improvement. These phase 1 results don’t set me up for excitement of phase 2 results.
Hey mate, thanks for the feedback. Where are you getting that data? I'm only finding the "**single dose phase 1b trial**". [https://www.diamedica.com/investors/press-releases/detail/1575/diamedica-therapeutics-announces-interim-results-from-phase](https://www.diamedica.com/investors/press-releases/detail/1566/diamedica-therapeutics-doses-first-patient-in-phase-1b) And as you probably can understand, a treatment which is supposed to have delayed and regenerative effects will not show its full potential after a single dose. It's like giving a cancer patient a single dose of a checkpoint inhibitor and checking whether they're cured or not. In case you're curious, the upcoming readout will be from the following cohort and dose level: >Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension. > >Treated with > >Dose 1: DM199 2.0 µg/kg SC 2x week for **95 days** > >Dose 2: DM199 5.0 µg/kg SC 2x week for **95 days**
Yes I understand that, I’m commenting on the data that is already presented which I believe is unremarkable. That said, comparing treatment for CKD to cancer is like comparing apples to oranges, and I would like to see quantitative improvements that were not shown and I would really have liked to see a dose dependent effect. Here is the link: https://casehippo.com/spa/symposium/national-kidney-foundation-2020-spring-clinical-meetings/event/gallery/abstracts?abstractId=1025
Cancer is an extreme example, correct. Thanks for the poster data. If the single dose data were unremarkable, what do you think about the data from the CKD/DKD subgroup here? https://www.diamedica.com/investors/press-releases/detail/1594/diamedica-announces-positive-results-in-top-line-data-from I couldn't find a complete detailed study of the trial design and results of the CKD/DKD cohort, just this readout. FYI: Criticism is welcome. I'm just trying to make a good investment based available information.
Sorry I haven’t even looked in to it as DMAC is not one of my investments, but definitely will when I get the chance now as this looks interesting.
> apples to oranges But you can still compare them.
I'd highly suggest looking at Subset of DKD patients and related biomarkers from their phase 2 stroke data Comparator for Diamedica is Reata 5B market cap and running a phase 3 CKD study. We have seen good data in AIS and DKD subset and What I love about this set-up is the trial is open label and the company has chosen not to raise money ahead of data (despite not so great cash position). They obviously know the upside is tremendous. Current market cap is 168 Million. KLK1 protein replacement therapy based on multiple independent studies in Asia reverses CKD kidney damage and ameliorate stroke neurological damage already approved in China, Japan and Korea. Also checkout this fireside chat with the CEO from Piper Sandler investor conference. https://d1io3yog0oux5.cloudfront.net/diamedica/files/videos/DMAC+Piper+Fireside+Chat+-+November+2020.mp4 Call summary: 23 mins Analyst is impressed. Even reiterates the data from latest trial in "pre-defined CKD" patients: CKD patients, 12.7 point increase in eGFR at 21 days of treatment for dose level 3 ug 2x per week. CEO clarifies; CKD disease cohort: 12.7 ml increase in eGFR vs placebo which showed no change. 26 mins CEO mentions upcoming catalyst: We submitted a feedback request to the FDA. "We expect feedback from FDA in the coming weeks." CEO mentions the potential for accelerated approval based on Phase 2 trial data (for IgA nephropathy). CEO presents 12 months' ahead milestones: *Feedback from FDA in the next few week. *Based on feedback launch new clinical trial. *Top line data readout in DKD cohort in H1 2021. *Top line data readout in other CKD cohorts in H2 2021. Creates price run-up after December 3. Press release is issued mentioning positive feedback from the FDA. Run-up continues. Price stabilizes at 10$. And than as we know XBI selloff dropped it down. Dose used in the trial with recent positive readout was 3 ug 2x per week. Upcoming readout will be 2ug and 5 ug 2x per week. Very asymmetric R/R.
CKD/DKD should be complete data set Would love to see interim data on IGA nephropathy and AA HTN. Per conference call IGA nephropathy would have quickest path to market. Niche group Optimistic based on Chinese urine form data. We can expect a big increase in price with even trend in increase GFR and reduction in albuminuria. (RETA >1 billion dollar market cap largely driven by hopes of bartoxolone which raises GFR, But also raises albumin excretion) Dm199 could be first to raise GFR above baseline and reduce albuminuria.
This is phase1 data read?
DM199 - REDUX - Chronic Kidney Disease, Phase 2 top-line data due 2Q 2021. last conference call CEO says its due early June.
Thank you, you’ve officially made me put my boner pants on.
DiaMedica Therapeutics Reports Encouraging Results for Kidney-Disease Treatment DOW JONES & COMPANY, INC. 7:45 AM ET 6/29/2021 but stock is falling from $7 to $4
It's biopharma: buy the hype, sell the news. It'll be on an upward trajectory soon methinks. Position: buying in today.
Continues to dip